NURIX THERAPEUTICS, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
NURIX THERAPEUTICS, INC. (NRIX) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $1.60 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-05-31 was $0.00.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-02-28 was $1.60M, a 27.48% increase year-over-year.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-11-30 was $0.00.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-08-31 was $977.00K, a 13.21% increase year-over-year.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $2.23M, a 4.55% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $2.13M, a 4.35% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $2.23M, a 14.02% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $1.96M, a 5.10% decline from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $1.60M 10-Q · filed 2026-07-09 | $1.60M derived: sum of 3 quarters · filed 2026-07-09 | $2.57M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $1.60M 10-Q · filed 2026-04-08 | $1.60M derived: sum of 2 quarters · filed 2026-04-08 | $2.57M derived: sum of 3 quarters · filed 2026-04-08 | $2.57M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $977.00K derived: sum of 2 quarters · filed 2026-01-28 | $977.00K derived: sum of 3 quarters · filed 2026-07-09 | $2.23M 10-K · filed 2026-01-28 |
| 2025-08-31 | $977.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $977.00K derived: sum of 2 quarters · filed 2026-07-09 | $2.23M 10-Q · filed 2025-10-09 | $2.23M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $1.25M 10-Q · filed 2026-07-09 | $1.25M derived: sum of 3 quarters · filed 2026-07-09 | $2.12M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $1.25M 10-Q · filed 2026-04-08 | $1.25M derived: sum of 2 quarters · filed 2026-04-08 | $2.12M derived: sum of 3 quarters · filed 2026-04-08 | $2.12M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $863.00K derived: sum of 2 quarters · filed 2026-01-28 | $863.00K derived: sum of 3 quarters · filed 2026-01-28 | $2.13M 10-K · filed 2026-01-28 |
| 2024-08-31 | $863.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $863.00K derived: sum of 2 quarters · filed 2025-10-09 | $2.13M 10-Q · filed 2025-10-09 | $2.13M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $1.27M 10-Q · filed 2025-07-09 | $1.27M derived: sum of 3 quarters · filed 2026-01-28 | $2.04M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $1.27M 10-Q · filed 2025-04-08 | $1.27M derived: sum of 2 quarters · filed 2026-01-28 | $2.04M derived: sum of 3 quarters · filed 2026-01-28 | $2.04M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $776.00K derived: sum of 2 quarters · filed 2026-01-28 | $776.00K derived: sum of 3 quarters · filed 2026-01-28 | $2.23M 10-K · filed 2026-01-28 |
| 2023-08-31 | $776.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $776.00K derived: sum of 2 quarters · filed 2024-10-11 | $2.23M 10-Q · filed 2024-10-11 | $2.23M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $1.45M 10-Q · filed 2024-07-11 | $1.45M derived: sum of 3 quarters · filed 2025-01-28 | $2.34M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $1.45M 10-Q · filed 2024-04-10 | $1.45M derived: sum of 2 quarters · filed 2025-01-28 | $2.34M derived: sum of 3 quarters · filed 2025-01-28 | $2.34M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $891.00K derived: sum of 2 quarters · filed 2025-01-28 | $891.00K derived: sum of 3 quarters · filed 2025-01-28 | $1.96M 10-K · filed 2025-01-28 |
| 2022-08-31 | $891.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $891.00K derived: sum of 2 quarters · filed 2023-10-12 | $1.96M 10-Q · filed 2023-10-12 | $1.96M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $1.06M 10-Q · filed 2023-07-13 | $1.06M derived: sum of 3 quarters · filed 2023-07-13 | $2.08M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $1.06M 10-Q · filed 2023-04-13 | $1.06M derived: sum of 2 quarters · filed 2023-04-13 | $2.08M derived: sum of 3 quarters · filed 2023-04-13 | $2.08M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $1.02M derived: sum of 2 quarters · filed 2023-02-09 | $1.02M derived: sum of 3 quarters · filed 2023-02-09 | $2.06M 10-K · filed 2023-02-09 |
| 2021-08-31 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $1.02M derived: sum of 2 quarters · filed 2022-10-06 | $2.06M 10-Q · filed 2022-10-06 | |
| 2021-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $1.04M 10-Q · filed 2022-07-07 | ||
| 2021-02-28 | $1.04M 10-Q · filed 2022-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |